Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.

The world's first human trial of whether a drug can essentially make a person's cells younger sets up a reality check for one ...

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now ...

Now he has a company that is trying to change the way we think about the so-called dark genome or noncoding DNA. Previously ...

Reversing cellular age isn’t science fiction, but the biology is more complicated than either the skeptics or the hype ...

First human receives reverse-aging gene therapy in groundbreaking trial targeting glaucoma, using cellular reprogramming to ...

A participant in a landmark clinical trial has been given a cellular-reprogramming treatment that aims to rejuvenate damaged ...

The approach relies on “reprogramming” cells to a younger state. It’s one of many strategies being explored by biotech ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the "recipe" for the transformation. Researchers at Lund University have now created ...

Pluristyx, a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, today announced the Japanese Patent Office (JPO) issued a ...